The financing agreement is extremely good for both the company and investors.
The "toxic" convertible notes you're referring to (most of us understand these, but I'll explain this to you) are the ones that are convertible almost immediately after the funds are given to the company. The reason those shares are convertible that soon is that the outlook is much more of a question mark for those companies (some still in the start-up phase, some not earning any money), so the lender needs to be able to convert as soon as possible otherwise the share price could deteriorate to a point where they'll have trouble getting their loan back through share conversion. RXMD was fortunate enough to enter into the current financing agreement simply because it's a reputable company and has a great financial outlook.
When an agreement like the one RXMD entered into doesn't allow for conversion to happen short-term, it means the lender has an expectation the company will be able to pay at least part of the loan back by means other than share conversion (AKA CASH MONEY $$$$$). Furthermore, it shows RXMD is looking not only to increase business but also protect its investors.
News 
Market Data 
Discover 
AI
